Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) (TDACS)

11. Juni 2026 aktualisiert von: Centre Hospitalier St Anne

Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized Double-Blind Controlled Trial

Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized Double-Blind Controlled Trial

Studienübersicht

Detaillierte Beschreibung

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by attentional difficulties and/or hyperactivity-impulsivity (American Psychiatric Association, 2013). Its treatment is primarily based on a multimodal approach, with first-line pharmacological management using methylphenidate (Ritalin®, Medikinet®, etc.).

However, given the limitations of pharmacological treatments (side effects, contraindications, and risks of misuse), alternative approaches such as transcranial direct current stimulation (tDCS) are generating increasing interest.

tDCS is a non-invasive, safe, and low-cost neuromodulation technique that delivers a low-intensity electrical current through electrodes placed on the scalp. It is well tolerated, with mild and transient adverse effects (tingling sensations, local skin redness, mild fatigue), making it a particularly safe approach. Its low cost and ease of use allow for broad accessibility, including in resource-limited healthcare settings.

In ADHD, tDCS targets the left dorsolateral prefrontal cortex, a key region involved in attention and executive functions. Early studies have reported encouraging results in terms of both efficacy and tolerability, particularly when combined with psychotherapeutic interventions.

The aim of this study is to evaluate the efficacy of tDCS in patients with ADHD.

The findings will support the potential future integration of tDCS into the management of ADHD resistant to conventional treatments.

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Unzutreffend

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Adult patient aged 18 to 60 years inclusive
  • Patient diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD), combined or predominantly inattentive presentation, previously established by a healthcare professional
  • Patients must be registered in the active caseload of the Adult Neurodevelopmental Disorders Unit (STNDA)
  • Stable psychotropic medication regimen for at least four weeks prior to inclusion, in terms of both molecule and dosage, particularly for methylphenidate, or no current psychotropic treatment. Medication must remain unchanged throughout study participation, unless medically justified changes are required
  • Patient with a cognitive status deemed sufficient by the unit's referring psychiatrist to ensure appropriate completion of the scales and tests included in the protocol
  • Free, informed, and written consent

Exclusion Criteria:

•General condition impairment (severe fatigue or marked weakness, convalescence after an acute illness or surgery, or recent alcohol consumption)

Psychiatric and neurological disorders

  • Diagnosis of Autism Spectrum Disorder (ASD)
  • Diagnosis of personality disorder (Cluster A, B, C, or other), according to DSM-5-TR
  • Diagnosis of schizophrenia spectrum disorder or other psychotic disorders according to DSM-5-TR
  • Diagnosis of bipolar disorder with manic episode or history of manic episodes according to DSM-5-TR
  • Confirmed neurological disorder
  • Epilepsy or history of epileptic seizures

Medical comorbidities

  • Patient with known or suspected cardiac disease
  • Patient with severe pulmonary disease
  • Patient with cerebrovascular disease (e.g., stroke)

Dermatological and surgical contraindications

  • Patient with scalp lesions, open wounds, or skin conditions (severe acne, herpes, burns, skin fissures)
  • Patient with severe dermatitis, oozing eczema, or fragile scalp
  • Patient with major surgical scars
  • Patient with recent craniotomy

Implantable devices and materials

• Patient with a pacemaker or intracranial electrodes, presence of intracranial metal, or skull defects (e.g., post-craniectomy or trepanation without reconstruction)

Other criteria:

  • Simultaneous participation in another non-pharmacological intervention provided in the STNDA day hospital (e.g., psychoeducation, cognitive remediation, body expression therapy, emotional regulation training)
  • Patient with non-pathological ASRS screening scores (fewer than 4 of the first 6 items rated "Very often")
  • Insufficient proficiency in the French language
  • Patient under legal guardianship, curatorship, or judicial protection
  • Pregnant or breastfeeding patient (based on clinical interview)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Schein-Komparator: tDCS sham
The placebo (sham) treatment will follow an identical protocol in terms of session duration, frequency, and overall procedure. Stimulation will be simulated, with a brief ramp-up and ramp-down of current at the beginning and end of the session, without actual stimulation during the remainder of the session, in order to mimic the initial sensations of active tDCS.

Repeated sessions of transcranial direct current stimulation (tDCS):

5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4

Experimental: tactive tDCS

Active transcranial direct current stimulation (tDCS): 2 mA stimulation for 20 minutes.

Repeated sessions of transcranial direct current stimulation (tDCS):

5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4

Repeated sessions of transcranial direct current stimulation (tDCS):

5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Inattention Symptoms Assessed by the Adult ADHD Self-Report Scale (ASRS) from Baseline to Immediately After tDCS
Zeitfenster: Baseline and immediately after the last tDCS session
The efficacy of tDCS will be assessed by measuring the change in inattention symptoms using the Adult ADHD Self-Report Scale (ASRS). The ASRS is a self-report questionnaire used to evaluate ADHD symptoms in adults. A decrease in the ASRS inattention score indicates an improvement in inattention symptoms.
Baseline and immediately after the last tDCS session

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Processing Speed Assessed by the WAIS-IV Coding and Symbol Search Subtests
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Processing speed will be assessed using the Coding and Symbol Search subtests of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV). Changes in scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Change in Working Memory Assessed by the WAIS-IV Digit Span Subtest
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Working memory will be assessed using the Digit Span subtest of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV). Changes in scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Change in Selective Attention Assessed by the d2-R Test of Attention
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Selective attention will be assessed using the d2-R Test of Attention. Changes in attention performance scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Change in Emotional Regulation Assessed by the Difficulties in Emotion Regulation Scale - French Version (DERS-F)
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Emotional regulation will be assessed using the Difficulties in Emotion Regulation Scale - French Version (DERS-F). Changes in emotional regulation scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Change in Anxiety and Depression Symptoms Assessed by the Hospital Anxiety and Depression Scale (HADS)
Zeitfenster: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Anxiety and depression symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS). Changes in anxiety and depression scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Incidence of Adverse Events Related to tDCS
Zeitfenster: From the first tDCS session through 6 weeks after the last tDCS session
The safety and tolerability of tDCS will be assessed by comparing the frequency and nature of adverse events reported in the active tDCS group and the sham tDCS group.
From the first tDCS session through 6 weeks after the last tDCS session

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juni 2026

Primärer Abschluss (Geschätzt)

10. Juni 2026

Studienabschluss (Geschätzt)

20. Februar 2028

Studienanmeldedaten

Zuerst eingereicht

21. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. Juni 2026

Zuerst gepostet (Tatsächlich)

17. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. Juni 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Transcranial direct current stimulation (tDCS)

Abonnieren